Literature DB >> 17230622

A case of scirrhous gastric cancer with peritonitis carcinomatosa controlled by TS-1 + paclitaxel for 36 mo after diagnosis.

Yusuke Koizumi1, Hirozumi Obata, Akinori Hara, Takashi Nishimura, Kenichiro Sakamoto, Yoshihide Fujiyama.   

Abstract

A 34-year-old female complaining of abdominal fullness was diagnosed as scirrhous gastric cancer (type 4') with peritonitis carcinomatosa in July 2002. A combined chemotherapy regimen was selected to control massive ascites; TS-1 80 mg/m(2) was given orally on d 1-14, 22-35, and paclitaxel 50 mg/m(2) was administered intravenously on d 1, 8, 22 and 29. After 2 courses of this regimen, the primary tumor was markedly reduced, and ascites completely vanished. Alopecia (grade 1, since d 30), leukocytopenia (grade 2, on d 34) and anemia (grade 2, on d 34) were the only adverse events throughout the following courses. The chemotherapy was effective for 28 mo, and then it was discontinued upon the patientos own request, and she survived for 36 mo after diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17230622      PMCID: PMC4065908          DOI: 10.3748/wjg.v13.i3.470

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  7 in total

1.  Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.

Authors:  Y Sakata; A Ohtsu; N Horikoshi; K Sugimachi; Y Mitachi; T Taguchi
Journal:  Eur J Cancer       Date:  1998-10       Impact factor: 9.162

2.  Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival.

Authors:  Dan Green; Sergio Ponce de Leon; Eucario Leon-Rodriguez; Ricardo Sosa-Sanchez
Journal:  Am J Clin Oncol       Date:  2002-02       Impact factor: 2.339

3.  Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.

Authors:  Yuji Ueda; Hisakazu Yamagishi; Daisuke Ichikawa; Jun Morii; Kinya Koizumi; Naoki Kakihara; Masataka Shimotsuma; Atsushi Takenaka; Tetsuro Yamashita; Hideaki Kurioka; Masahiko Nishiyama; Satoshi Morita; Kanae Nakamura; Junichi Sakamoto
Journal:  Oncology       Date:  2005-09-01       Impact factor: 2.935

4.  Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.

Authors:  Y Yamada; K Shirao; A Ohtsu; N Boku; I Hyodo; H Saitoh; Y Miyata; T Taguchi
Journal:  Ann Oncol       Date:  2001-08       Impact factor: 32.976

5.  Clinicopathological features of patients with Borrmann type IV gastric carcinoma.

Authors:  Dong Yi Kim; Hyeong Rok Kim; Young Jin Kim; ShinKon Kim
Journal:  ANZ J Surg       Date:  2002-10       Impact factor: 1.872

6.  Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma.

Authors:  Chin-Yau Chen; Chew-Wen Wu; Su-Shun Lo; Mao-Chin Hsieh; Wing-Yiu Lui; King-Han Shen
Journal:  Hepatogastroenterology       Date:  2002 May-Jun

Review 7.  Taxol (paclitaxel): mechanisms of action.

Authors:  S B Horwitz
Journal:  Ann Oncol       Date:  1994       Impact factor: 32.976

  7 in total
  1 in total

Review 1.  Paclitaxel chemotherapy for the treatment of gastric cancer.

Authors:  Junichi Sakamoto; Takanori Matsui; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.